# Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

> **NCT00908232** · PHASE2 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 163 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00908232
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2015-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908232, "Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00908232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*